Daiichi Sankyo Company, Limited (4568) Press Release
Notice Regarding NTK’s Filing of Appeal in Damages Claim Against Daiichi Sankyo
Earlier from Daiichi Sankyo
- Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
- Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- Daiichi Sankyo: Receives Favorable Judgment in Damage Claim Filed by NTK